BIOCHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK MUCOSAL MELANOMA

被引：64

作者：

Bartell, Holly L. ^{[2
]}

Bedikian, Agop Y. ^{[1
]}

Papadopoulos, Nicholas E. ^{[1
]}

Dett, Tina K. ^{[1
]}

Ballo, Matthew T. ^{[3
]}

Myers, Jeffrey N. ^{[4
]}

Hwu, Patrick ^{[1
]}

Kim, Kevin B. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA

[2] Univ Texas Houston, Sch Med, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg Oncol, Houston, TX 77030 USA

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2008年 / 30卷 / 12期

关键词：

head and neck; mucosal; melanoma; systemic therapy; biochemotherapy;

D O I：

10.1002/hed.20910

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 [耳鼻咽喉科学];

摘要：

Background. No systemic therapy regimen has been recognized as effective for metastatic mucosal melanoma of the head and neck. We retrospectively analyzed the effectiveness of biochemotherapy in patients with advanced head and neck mucosal melanoma. Methods. We evaluated the medical records of 15 patients at our institution who had received various biochemotherapy regimens for advanced head and neck mucosal melanoma. Results. After a median follow-up duration of 13 months, 3 patients (20%) had partial response, and 4 patients (27%) had complete response, The median time to disease progression for all 15 patients was 10 months, The median overall survival duration for all patients was 22 months. Conclusions. Although this was a small study, our results, especially the high complete response and overall response rates, indicate that biochemotherapy for advanced head and neck mucosal melanoma should be considered as a systemic treatment option for patients with this aggressive malignancy. (C) 2008 Wiley Periodicals, Inc. Head Neck 30: 15921598, 2008

引用

页码：1592 / 1598

页数：7

共 34 条

[1]

ATKINS MB, 2003, P AN M AM SOC CLIN, V22, pA708

[2]

CHEMOIMMUNOTHERAPY OF ADVANCED MALIGNANT-MELANOMA - SEQUENTIAL ADMINISTRATION OF SUBCUTANEOUS INTERLEUKIN-2 AND INTERFERON-ALPHA AFTER INTRAVENOUS DACARBAZINE AND CARBOPLATIN OR INTRAVENOUS DACARBAZINE, CISPLATIN, CARMUSTINE AND TAMOXIFEN [J].

ATZPODIEN, J ;

HANNINEN, EL ;

KIRCHNER, H ;

FRANZKE, A ;

KORFER, A ;

VOLKENANDT, M ;

DUENSING, S ;

SCHOMBURG, A ;

CHAITCHIK, S ;

POLIWODA, H .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (06) :876-881

[3]

BEDIKIAN AY, 2005, P AM SOC CLIN ONCOL

[4]

Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO

[5]

2-G

[6]

CHAUDHRY AP, 1958, CANCER-AM CANCER SOC, V11, P923, DOI 10.1002/1097-0142(195809/10)11:5<923::AID-CNCR2820110507>3.0.CO

[7]

2-1

[8]

CONLEY J, 1974, ARCH OTOLARYNGOL, V99, P315

[9]

Somatic activation of KIT in distinct subtypes of melanoma [J].

Curtin, John A. ;

Busam, Klaus ;

Pinkel, Daniel ;

Bastian, Boris C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4340-4346

[10]

Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

← 1 2 3 4 →